Vivos Therapeutics Inc
NASDAQ:VVOS
Vivos Therapeutics Inc
Vivos Therapeutics, Inc. is a medical technology company which engages in the development and commercialization of treatment alternatives for patients with sleep disordered breathing (SDB). The company is headquartered in Highlands Ranch, Colorado and currently employs 158 full-time employees. The company went IPO on 2020-12-11. The firm is focused on the development and commercialization to dental practices of a patented oral appliance technology and related protocols called the Vivos System. The firm's Vivos System is a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for people with sleep disordered breathing (SDB), including mild-to-moderate obstructive sleep apnea (OSA). The Company’s business model is focused on dentists, and the Company’s program to train dentists and offer them other value-added services in connection with their ordering and use of the Vivos System for patients is called the Vivos Integrated Practice (VIP) program. Its primary product used in the Vivos System is the mRNA appliance, a specifically designed, custom oral appliance that is worn primarily in the evening hours and overnight and is available for adults.
Vivos Therapeutics, Inc. is a medical technology company which engages in the development and commercialization of treatment alternatives for patients with sleep disordered breathing (SDB). The company is headquartered in Highlands Ranch, Colorado and currently employs 158 full-time employees. The company went IPO on 2020-12-11. The firm is focused on the development and commercialization to dental practices of a patented oral appliance technology and related protocols called the Vivos System. The firm's Vivos System is a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for people with sleep disordered breathing (SDB), including mild-to-moderate obstructive sleep apnea (OSA). The Company’s business model is focused on dentists, and the Company’s program to train dentists and offer them other value-added services in connection with their ordering and use of the Vivos System for patients is called the Vivos Integrated Practice (VIP) program. Its primary product used in the Vivos System is the mRNA appliance, a specifically designed, custom oral appliance that is worn primarily in the evening hours and overnight and is available for adults.
Revenue Growth: Q3 2025 revenue rose 76% year-over-year to $6.8 million, driven by the Sleep Center of Nevada (SCN) acquisition and expansion into diagnostic and treatment services.
Business Model Pivot: The company’s shift toward acquiring and affiliating with medical sleep practices is showing strong early results, with management describing Q3 as an inflection point.
Operating Costs: Costs increased significantly due to investments in SCN integration, hiring, and preparing for future growth, resulting in a higher net loss.
Capacity Constraints: Patient demand is outpacing Vivos’ current provider capacity, but new hires and expanded facilities are expected to improve throughput over the next 3–6 months.
Scalability & Expansion: Management emphasized that their new model is replicable and scalable, with additional affiliations and acquisitions planned and negotiations ongoing in new markets.
Outlook: Vivos expects continued revenue growth and aims for cash flow breakeven as more providers become licensed and credentialed, though the exact timing was not specified.
